A UK study estimates that children who receive the human papillomavirus (HPV) vaccine at around 12–13 have a close to zero risk of dying from cervical cancer before the age of 30. Both outlets report that the findings are based on modelling that projects how vaccination timing and coverage could affect long-term cancer outcomes. The study’s conclusion is focused specifically on deaths occurring before age 30, rather than overall cervical cancer risk across a lifetime. The reporting also notes that the protective effect is linked to administering the vaccine during early adolescence, before many people would have exposure to HPV. While the study suggests very low mortality risk in the pre-30 age group, the articles describe it as an estimate from a study rather than direct observation of decades-long outcomes. Overall, the coverage aligns on the same core message: vaccinating at ages 12–13 is associated with an extremely low estimated risk of dying from cervical cancer before age 30.